Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 112

1.

Cardiovascular comorbidity increases the risk for renal failure during prophylactic lithium treatment.

Aiff H, Attman PO, Ramsauer B, Schön S, Svedlund J.

J Affect Disord. 2019 Jan 15;243:416-420. doi: 10.1016/j.jad.2018.09.044. Epub 2018 Sep 17.

PMID:
30268957
2.

Compliance with the safety guidelines for long-term lithium treatment in Sweden.

Golic M, Aiff H, Attman PO, Ramsauer B, Schön S, Svedlund J.

J Psychopharmacol. 2018 Oct;32(10):1104-1109. doi: 10.1177/0269881118780014. Epub 2018 Jun 13.

PMID:
29896998
3.

A practical approach to low protein diets in Sweden- 45 years of clinical use.

Eyre S, Faxén-Irving G, Attman PO, Evans M, Windahl K, Wegener S, Andersén C, Nykvist-Raanaes K, Einemo S, Carrero JJ.

BMC Nephrol. 2016 Jul 19;17(1):89. doi: 10.1186/s12882-016-0295-6. Review.

4.

Effects of 10 to 30 years of lithium treatment on kidney function.

Aiff H, Attman PO, Aurell M, Bendz H, Ramsauer B, Schön S, Svedlund J.

J Psychopharmacol. 2015 May;29(5):608-14. doi: 10.1177/0269881115573808. Epub 2015 Mar 3.

PMID:
25735990
5.

Reply to letter to the editor.

Aiff H, Attman PO, Bendz H, Ramsauer B, Schön S, Svedlund J.

J Psychopharmacol. 2014 Dec;28(12):1190. doi: 10.1177/0269881114553153. No abstract available.

PMID:
25392463
6.

End-stage renal disease associated with prophylactic lithium treatment.

Aiff H, Attman PO, Aurell M, Bendz H, Schön S, Svedlund J.

Eur Neuropsychopharmacol. 2014 Apr;24(4):540-4. doi: 10.1016/j.euroneuro.2014.01.002. Epub 2014 Jan 17.

PMID:
24503277
7.

The impact of modern treatment principles may have eliminated lithium-induced renal failure.

Aiff H, Attman PO, Aurell M, Bendz H, Schön S, Svedlund J.

J Psychopharmacol. 2014 Feb;28(2):151-4. doi: 10.1177/0269881113516202. Epub 2013 Dec 17.

PMID:
24346809
8.

Dual PPAR α / γ Agonism Normalizes Lipoprotein Profile of Renal Dyslipidemia.

Samuelsson O, Attman PO, Gause-Nilsson I, Svensson MK, Alaupovic P.

PPAR Res. 2013;2013:391628. doi: 10.1155/2013/391628. Epub 2013 Mar 28.

9.

Oxidative stress and inflammation in renal patients and healthy subjects.

Lee DM, Jackson KW, Knowlton N, Wages J, Alaupovic P, Samuelsson O, Saeed A, Centola M, Attman PO.

PLoS One. 2011;6(7):e22360. doi: 10.1371/journal.pone.0022360. Epub 2011 Jul 28.

10.

Lipoprotein abnormalities in patients with atherosclerotic renovascular disease.

Nowakowska Fortuna E, Herlitz H, Saeed A, Attman PO, Jensen G, Alaupovic P, Guron G.

Kidney Blood Press Res. 2011;34(5):311-9. doi: 10.1159/000325648. Epub 2011 May 26.

11.

The effect of decreasing renal function on lipoprotein profiles.

Attman PO, Samuelsson O, Alaupovic P.

Nephrol Dial Transplant. 2011 Aug;26(8):2572-5. doi: 10.1093/ndt/gfq762. Epub 2011 Jan 10.

PMID:
21220758
12.

Renal failure occurs in chronic lithium treatment but is uncommon.

Bendz H, Schön S, Attman PO, Aurell M.

Kidney Int. 2010 Feb;77(3):219-24. doi: 10.1038/ki.2009.433. Epub 2009 Nov 25.

13.

Dyslipidemia of kidney disease.

Attman PO, Samuelsson O.

Curr Opin Lipidol. 2009 Aug;20(4):293-9. doi: 10.1097/MOL.0b013e32832dd832. Review.

PMID:
19512921
14.

Positive effects of protein restriction in patients with chronic kidney disease.

Eyre S, Attman PO, Haraldsson B.

J Ren Nutr. 2008 May;18(3):269-80. doi: 10.1053/j.jrn.2007.11.013.

PMID:
18410883
15.

Protein restriction and body composition in renal disease.

Eyre S, Attman PO.

J Ren Nutr. 2008 Mar;18(2):167-86. doi: 10.1053/j.jrn.2007.08.006.

PMID:
18267210
16.

Candesartan cilexetil in haemodialysis patients.

Ottosson P, Attman PO, Agren AC, Samuelsson O.

Clin Drug Investig. 2003;23(8):545-50.

PMID:
17535067
17.

Effect of fluvastatin on apolipoprotein-defined lipoprotein subclasses in patients with chronic renal insufficiency.

Alaupovic P, Attman PO, Knight-Gibson C, Mulec H, Weiss L, Samuelsson O.

Kidney Int. 2006 May;69(10):1865-71.

18.

Prevention of clot formation during haemodialysis using the direct thrombin inhibitor melagatran in patients with chronic uraemia.

Attman PO.

Nephrol Dial Transplant. 2006 Jun;21(6):1738. Epub 2005 Dec 19. No abstract available.

PMID:
16364986
19.

Prevention of clot formation during haemodialysis using the direct thrombin inhibitor melagatran in patients with chronic uraemia.

Attman PO, Ottosson P, Samuelsson O, Eriksson UG, Eriksson-Lepkowska M, Fager G.

Nephrol Dial Transplant. 2005 Sep;20(9):1889-97. Epub 2005 May 31.

PMID:
15928099
20.

Influence of severe renal impairment on the pharmacokinetics and pharmacodynamics of oral ximelagatran and subcutaneous melagatran.

Eriksson UG, Johansson S, Attman PO, Mulec H, Frison L, Fager G, Samuelsson O.

Clin Pharmacokinet. 2003;42(8):743-53.

PMID:
12846595
21.

Dialysis modalities and dyslipidemia.

Attman PO, Samuelsson O, Johansson AC, Moberly JB, Alaupovic P.

Kidney Int Suppl. 2003 May;(84):S110-2. Review.

PMID:
12694322
22.

Alterations in lipoprotein composition in peritoneal dialysis patients.

Moberly JB, Attman PO, Samuelsson O, Johansson AC, Knight-Gibson C, Alaupovic P.

Perit Dial Int. 2002 Mar-Apr;22(2):220-8.

PMID:
11990407
23.

Lipoprotein particle abnormalities and the impaired lipolysis in renal insufficiency.

Lee DM, Knight-Gibson C, Samuelsson O, Attman PO, Wang CS, Alaupovic P.

Kidney Int. 2002 Jan;61(1):209-18.

24.

Fluvastatin improves lipid abnormalities in patients with moderate to advanced chronic renal insufficiency.

Samuelsson O, Attman PO, Knight-Gibson C, Mulec H, Weiss L, Alaupovic P.

Am J Kidney Dis. 2002 Jan;39(1):67-75.

PMID:
11774104
25.

Do high-flux dialysis membranes affect renal dyslipidemia?

Ottosson P, Attman PO, Knight C, Samuelsson O, Weiss L, Alaupovic P.

ASAIO J. 2001 May-Jun;47(3):229-34.

PMID:
11374763
26.

Limitations in anthropometric calculations of total body water in patients on peritoneal dialysis.

Johansson AC, Samuelsson O, Attman PO, Bosaeus I, Haraldsson B.

J Am Soc Nephrol. 2001 Mar;12(3):568-73.

27.

Is smoking a risk factor for progression of chronic renal failure?

Samuelsson O, Attman PO.

Kidney Int. 2000 Dec;58(6):2597. No abstract available.

28.

Expert working group report on nutrition in adult patients with renal insufficiency (Part 2 of 2).

Toigo G, Aparicio M, Attman PO, Cano N, Cianciaruso B, Engel B, Fouque D, Heidland A, Teplan V, Wanner C.

Clin Nutr. 2000 Aug;19(4):281-91. Review. No abstract available.

PMID:
10952801
29.

Dyslipidemia in peritoneal dialysis--relation to dialytic variables.

Johansson AC, Samuelsson O, Attman PO, Haraldsson B, Moberly J, Knight-Gibson C, Alaupovic P.

Perit Dial Int. 2000 May-Jun;20(3):306-14.

PMID:
10898048
30.

Expert Working Group report on nutrition in adult patients with renal insufficiency (part 1 of 2).

Toigo G, Aparicio M, Attman PO, Cano N, Cianciaruso B, Engel B, Fouque D, Heidland A, Teplan V, Wanner C.

Clin Nutr. 2000 Jun;19(3):197-207. Review. No abstract available.

PMID:
10895111
31.

Dimensions of arteriovenous fistulas in patients with autosomal dominant polycystic kidney disease.

Hadimeri H, Hadimeri U, Attman PO, Nyberg G.

Nephron. 2000 May;85(1):50-3.

PMID:
10773755
32.

Angiotensin I-converting enzyme gene polymorphism in non-diabetic renal disease.

Samuelsson O, Attman PO, Larsson R, Mulec H, Rymo L, Weiss L, Ricksten A.

Nephrol Dial Transplant. 2000 Apr;15(4):481-6.

PMID:
10727542
33.

Apolipoprotein C-III, hypertriglyceridemia and triglyceride-rich lipoproteins in uremia.

Moberly JB, Attman PO, Samuelsson O, Johansson AC, Knight-Gibson C, Alaupovic P.

Miner Electrolyte Metab. 1999 Jul-Dec;25(4-6):258-62.

PMID:
10681649
34.

[Hemodialysis cured severe lactic acidosis caused by metformin treatment].

Stefánsson B, Larsson B, Attman PO.

Lakartidningen. 1999 Dec 15;96(50):5622-4. Swedish. No abstract available.

PMID:
10643227
35.

Cadmium, mercury, and lead in kidney cortex of the general Swedish population: a study of biopsies from living kidney donors.

Barregård L, Svalander C, Schütz A, Westberg G, Sällsten G, Blohmé I, Mölne J, Attman PO, Haglind P.

Environ Health Perspect. 1999 Nov;107(11):867-71.

36.

Improved clearance of iohexol with longer haemodialysis despite similar Kt/V for urea.

Johnsson E, Attman PO, Samuelsson O, Haraldsson B.

Nephrol Dial Transplant. 1999 Oct;14(10):2407-12.

PMID:
10528665
37.

The plasma levels of homocysteine are elevated in moderate renal insufficiency but do not predict the rate of progression.

Samuelsson O, Lee DM, Attman PO, Knight-Gibson C, Mullen JK, Larsson R, Mulec H, Weiss L, Alaupovic P.

Nephron. 1999;82(4):306-11.

PMID:
10450032
38.

Lipoprotein abnormalities as a risk factor for progressive nondiabetic renal disease.

Attman PO, Alaupovic P, Samuelsson O.

Kidney Int Suppl. 1999 Jul;71:S14-7. Review.

PMID:
10412728
39.

Apolipoprotein B-containing lipoproteins in renal failure: the relation to mode of dialysis.

Attman PO, Samuelsson OG, Moberly J, Johansson AC, Ljungman S, Weiss LG, Knight-Gibson C, Alaupovic P.

Kidney Int. 1999 Apr;55(4):1536-42.

40.

The compositional abnormalities of lipoproteins in diabetic renal failure.

Attman PO, Knight-Gibson C, Tavella M, Samuelsson O, Alaupovic P.

Nephrol Dial Transplant. 1998 Nov;13(11):2833-41.

PMID:
9829487
41.

First clinical experience with a new concentrate system for dialysis with dry sodium chloride.

Alquist M, Attman PO, Ipsen R, Jönsson L, Hegbrant J.

ASAIO J. 1998 Sep-Oct;44(5):M592-5.

PMID:
9804502
42.

Complex apolipoprotein B-containing lipoprotein particles are associated with a higher rate of progression of human chronic renal insufficiency.

Samuelsson O, Attman PO, Knight-Gibson C, Larsson R, Mulec H, Weiss L, Alaupovic P.

J Am Soc Nephrol. 1998 Aug;9(8):1482-8.

43.

Body composition in patients treated with peritoneal dialysis.

Johansson AC, Samuelsson O, Haraldsson B, Bosaeus I, Attman PO.

Nephrol Dial Transplant. 1998 Jun;13(6):1511-7.

PMID:
9641184
44.

Body composition in renal failure and the effect of dialysis.

Johansson AC, Haraldsson B, Attman PO.

Appl Radiat Isot. 1998 May-Jun;49(5-6):665-6. No abstract available.

PMID:
9569573
45.

Progression of renal failure and lipids--is there evidence for a link in humans?

Attman PO.

Nephrol Dial Transplant. 1998 Mar;13(3):545-7. Review. No abstract available.

PMID:
9550623
46.

Progression of renal failure: role of apolipoprotein B-containing lipoproteins.

Attman PO, Samuelsson O, Alaupovic P.

Kidney Int Suppl. 1997 Dec;63:S98-101. Review.

PMID:
9407433
47.

Lipoprotein abnormalities are associated with increased rate of progression of human chronic renal insufficiency.

Samuelsson O, Mulec H, Knight-Gibson C, Attman PO, Kron B, Larsson R, Weiss L, Wedel H, Alaupovic P.

Nephrol Dial Transplant. 1997 Sep;12(9):1908-15.

PMID:
9306342
48.

Creatinine generation rate and lean body mass: a critical analysis in peritoneal dialysis patients.

Johansson AC, Attman PO, Haraldsson B.

Kidney Int. 1997 Mar;51(3):855-9.

49.

Lipid abnormalities in progressive renal insufficiency.

Attman PO, Samuelsson O, Alaupovic P.

Contrib Nephrol. 1997;120:1-10. Review. No abstract available.

PMID:
9257042
50.

Effect of gemfibrozil on lipoprotein abnormalities in chronic renal insufficiency: a controlled study in human chronic renal disease.

Samuelsson O, Attman PO, Knight-Gibson C, Kron B, Larsson R, Mulec H, Weiss L, Alaupovic P.

Nephron. 1997;75(3):286-94.

PMID:
9069450

Supplemental Content

Loading ...
Support Center